| Description | XmAb 5592 is a humanized, Fc-engineered antibody targeting HM1.24 with improved affinity for both FcγRIIIa and FcγRIIa receptors. It enhances lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro [1]. |
| In vitro | XmAb 5592 (0-1000 ng/mL) 在促进针对多发性骨髓瘤（MM）细胞的抗体依赖细胞介导的细胞毒性（ADCC）及抗体依赖性细胞吞噬（ADCP）方面表现出增强作用。相较于IgG1类似物，XmAb 5592 在5-27 ng/mL浓度区间内能显著提升所有测试的细胞系的ADCC效应，并增强巨噬细胞介导的ADCP [1]。在0-10000 ng/mL浓度范围内，即便在骨髓基质细胞（BMSCs）存在的条件下，XmAb 5592 亦可激发NK细胞通过脱颗粒作用强烈诱导MM细胞的裂解 [1]。 |
| In vivo | XmAb 5592（0.3-9 mg/kg；i.p.；周二次、每次七剂；RPMI8226荷瘤SCID小鼠）通过FcγR依赖机制，有效地抑制了搭载人类MM异种移植瘤的小鼠的肿瘤生长[1]。 |
| molecular weight | N/A |
| CAS | 1221901-33-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |